上市进程迈出关键一步 甘露藏药股份引入四家战略投资者

Core Insights - The strategic investment initiative by Gansu Tibetan Medicine Co., Ltd. has successfully raised approximately 174 million yuan through the introduction of four strategic investors, marking a significant milestone in the company's listing process [1][3]. Group 1: Strategic Investors - The strategic investors include a national-level fund, a Fortune 500 pharmaceutical state-owned enterprise, a local state-owned investment platform, and financial institutions, collectively referred to as the "strategic investment team" [1][2]. - The national-level fund involved is the Mixed Ownership Reform Fund, which is managed by China Chengtong Holdings Group and has an initial scale of 70.7 billion yuan, focusing on sectors such as healthcare and biopharmaceuticals [1][2]. Group 2: Future Development Plans - The company aims to leverage the strengths of its strategic investors in capital, industry, channels, and management to enhance its core competitiveness and promote high-quality development [3]. - The strategic investors were selected based on their ability to support the company's goal of expanding into mainland markets, particularly targeting Beijing, the Yangtze River Delta, and the Southwest regions [3].